This year, the predicted flurry of merger and acquisition (M&A) activity might not have materialised. However, as we near the end of the year, there were some big moves.
Roche announced this morning that its head of pharmaceuticals, Bill Anderson, is leaving the company to pursue "other opportunities" after four years in the role.